Pipeline 001


PROGRESS – Approaching Lead Candidate

Eliminating solid tumors without toxicity

A modified fusion protein, oNKo-001 aims to widen the therapeutic window of the IL-12 cytokine by reducing toxicity and enhancing its pharmacokinetic profile, all while maintaining its impressive anti-tumor function.

Interleukin-12 (IL-12) is a heterodimeric pro-inflammatory cytokine that plays a key role in regulating both the innate and adaptive immune system.  

With pluripotent effects, IL-12 potently promotes the anti-tumor function of the immune system, causing the activation and proliferation of cytotoxic lymphocytes such as T and NK cells while reprogramming suppressive cells such as tumor-associated macrophages (TAMs) and regulatory T cells.

While cytokines like IL-12 have strong anti-tumor activity in animal models, they have an extremely short half-life in the body and can induce severe toxicities associated with the activation of circulating immune cells. These major obstacles have prevented their use as therapeutic products.

Our most advanced pipeline asset, oNKo-001 is a reduced-potency IL-12 Fc fusion protein that has been specifically engineered to reduce toxicity and exhibit an enhanced pharmacokinetic profile, all whilst maintaining IL-12’s impressive anti-tumor function.